- Reports
- Lisa Graves
- Mary Bottari
- Wendell Potter
- Brendan Fischer
- Rebekah Wilce
- Sara Jerving
- Harriet Rowan
- Jonathan Rosenblum
- Will Dooling
- Emily Osborne
- Abdul Raziq
- Guest Contributor
- Archives
- Alex Carlin
- Anne Landman
- Bob Burton
- Chelsea Lawliss
- Diane Farsetta
- Eric Carlson
- Jennifer Page
- Jessica Opoien
- Jill Richardson
- John Stauber
- Judith Siers-Poisson
- Maxwell Abbott
- Megha Desai
- Monica Chang
- Osasumwen Izevbigie
- Patrick Moran
- Rebecca Sandler
- Ross Wolfarth
- Sarah Olson
- Sheldon Rampton
- Steve Horn
- Take Action
- Latest News
- Media
- SourceWatch
- Publications
- About Us
- Why Donate?
Leaked Documents Spur Investigation into Lilly Drug Marketing
A U.S. federal court judge has extended an injunction banning groups in the U.S. from adding a weblink to leaked internal documents on Eli Lilly's schizophrenia and bipolar disorder drug, Zyprexa. Despite the injunction, the documents have been distributed around the world from websites outside the U.S. Lilly also has problems on another front. The New York Times reports that "lawyers from the consumer protection division of the Illinois attorney general's office demanded that Lilly hand over marketing materials, e-mail messages, and other documents with information about promotion" of the drug. Vermont government investigators have made a similar order. At issue is whether Lilly hid information on weight gain and the associated risk of diabetes and also promoted the use of the drug for patients who didn't have schizophrenia or bipolar disorder.
Main Source:
New York Times, January 20, 2007 



